Choroidal Thickness and microRNA146 in Lupus Nephritis Patients
Received 17 March 2020
Accepted for publication 11 May 2020
Published 2 June 2020 Volume 2020:14 Pages 1503—1510
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Shaymaa Hassan Salah, 1 Hebatalla Samir Makled, 1 Hany ElMekawey, 1 Fatema T Elgengehy, 2 Basma M Medhat, 2 Noha M Abdel Baki, 2 Dina Koptan 3
1Ophthalmology Department, Kasr Alainy, Cairo University, Cairo, Egypt; 2Rheumatology and Rehabilitation, Kasr Alainy, Cairo University, Cairo, Egypt; 3Clinical Pathology, Kasr Alainy, Cairo University, Cairo, Egypt
Correspondence: Shaymaa Hassan Salah
Kasr Alainy Hospital, 1 Saray Al-Manial, Cairo 11559, Egypt
Purpose: To evaluate the choroidal thickness (CT) in the macular area in patients with lupus nephritis and to compare the results with both non-nephritic patients and normal control. To assess the relation of CT to serum microRNA146, disease duration, activity index, and medications.
Patients and Methods: Thirty-five SLE patients and thirty normal healthy controls were enrolled for this cross-sectional prospective study. All participants have undergone optical coherence tomography using RTVue OCT (Optovue Inc., Fremont, CA, USA). The scan used was the macular cross 6-mm line. We measured CT from the posterior edge of the retinal pigment epithelium (RPE) to the choroid-sclera junction at subfovea, and 750 μm both temporal and nasal to the fovea.
Results: The mean central subfoveal CT in patients was 275.7 ± 41.0 μm (214– 374 μm), and the mean central subfoveal CT in the control group was 364.5± 23.0 μm (323– 411μm). There was a significant thinning at all three points in patients compared to the control group (p< 0.001, Mann–Whitney U-test). In the patients group, subfoveal choroid in non-nephritic subgroup showed significant thinning compared to nephritic subgroup (p=0.032, Mann–Whitney U-test). Drusen-like deposits (DLDs) were detected in 22.9% (8/35) of patients and none in control (p=.023). MiRNA146 showed a significant positive correlation with nephritic lupus patients (r=0.036, P=0.04).
Conclusion: The choroidal thickness was significantly thicker among the nephritic lupus patients as compared to the non-nephritic subgroup. Both SLE patients’ subgroups are thinner than normal control. Subfoveal choroidal thickening can be considered a biomarker in nephritic lupus especially in conjunction with an increase in miRNA146a. All SLE patients are at risk of small Drusen-like deposits.
Keywords: choroidal thinning, lupus nephritis, miRNA146a, SLEDI
A Letter to the Editor has been published for this article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]